Ovid Therapeutics (OVID) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free OVID Stock Alerts $3.02 +0.02 (+0.67%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 7:00 AM | globenewswire.comOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 11 at 1:18 AM | americanbankingnews.comReviewing Ovid Therapeutics (NASDAQ:OVID) and Intellipharmaceutics International (OTCMKTS:IPCIF)May 10, 2024 | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives $8.08 Average PT from BrokeragesMay 9, 2024 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Price Target Cut to $3.50May 7, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Ovid TherapeuticsMay 7, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have giveMay 7, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) PT Lowered to $3.50 at CitigroupCitigroup cut their target price on shares of Ovid Therapeutics from $4.00 to $3.50 and set a "neutral" rating on the stock in a research note on Tuesday.May 2, 2024 | marketbeat.comResearch Analysts Offer Predictions for Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at B. Riley issued their Q1 2024 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, April 29th. B. Riley analyst K. Patel expects that the company willMay 1, 2024 | marketbeat.comFFT Wealth Management LLC Invests $1.27 Million in Ovid Therapeutics Inc. (NASDAQ:OVID)FFT Wealth Management LLC acquired a new position in Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 395,774 shares of the company's stock, valued at approximately $1,274,000. FFT Wealth Management LLC owMay 1, 2024 | marketbeat.comHC Wainwright Weighs in on Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Ovid Therapeutics in a research report issued on Monday, April 29th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.22) per shareApril 30, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationApril 30, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Now Covered by Analysts at B. RileyB. Riley initiated coverage on shares of Ovid Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $9.00 price target on the stock.April 18, 2024 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business GrowthApril 13, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Short Interest Down 23.7% in MarchOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 2,800,000 shares, a drop of 23.7% from the March 15th total of 3,670,000 shares. Based on an average daily trading volume, of 205,000 shares, the short-interest ratio is currently 13.7 days. Currently, 4.8% of the shares of the stock are short sold.April 5, 2024 | msn.comOvid Therapeutics gains on bullish view at WedbushApril 5, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Coverage Initiated at WedbushWedbush started coverage on Ovid Therapeutics in a report on Friday. They set an "outperform" rating and a $8.00 price objective on the stock.April 4, 2024 | globenewswire.comOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | msn.comMarinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy TreatmentMarch 29, 2024 | bizjournals.comMarinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twistMarch 22, 2024 | investing.comOvid therapeutics CEO acquires $50k in company stockMarch 22, 2024 | finance.yahoo.comOvid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock BuyingMarch 21, 2024 | insidertrades.comOvid Therapeutics Inc. (NASDAQ:OVID) CEO Jeremy M. Levin Acquires 18,248 SharesMarch 20, 2024 | marketbeat.comJeremy M. Levin Purchases 18,248 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) StockOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) CEO Jeremy M. Levin purchased 18,248 shares of the stock in a transaction dated Monday, March 18th. The shares were acquired at an average price of $2.76 per share, with a total value of $50,364.48. Following the transaction, the chief executive officer now owns 3,616,715 shares in the company, valued at $9,982,133.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.March 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsMarch 8, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | investing.comOvid Therapeutics Inc (OVID)February 28, 2024 | globenewswire.comOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | news.yahoo.comOvid-Elsie girls win third straight conference titleFebruary 17, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Short Interest UpdateOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 3,340,000 shares, an increase of 8.4% from the January 15th total of 3,080,000 shares. Based on an average daily trading volume, of 142,100 shares, the short-interest ratio is currently 23.5 days. Currently, 5.6% of the shares of the stock are sold short.February 17, 2024 | finance.yahoo.comOVID Mar 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comOVID Apr 2024 5.000 callFebruary 15, 2024 | msn.comTaysha transfers rights to 3 programs, extends cash runway into 2026February 6, 2024 | finance.yahoo.comOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | msn.comCirculatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illnessJanuary 18, 2024 | finance.yahoo.comOwning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),January 14, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Sees Large Increase in Short InterestOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,900,000 shares, a growth of 16.9% from the December 15th total of 2,480,000 shares. Based on an average daily trading volume, of 136,300 shares, the short-interest ratio is presently 21.3 days. Approximately 4.9% of the company's shares are short sold.January 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)January 2, 2024 | finance.yahoo.comEnavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 InhibitorsDecember 22, 2023 | benzinga.comOvid Therapeutics Stock (NASDAQ:OVID), Analyst Ratings, Price Targets, PredictionsDecember 21, 2023 | benzinga.comOvid Therapeutics Stock (NASDAQ:OVID) Dividends: History, Yield and DatesDecember 21, 2023 | msn.comBTIG Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationDecember 21, 2023 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Earns Buy Rating from Analysts at BTIG ResearchBTIG Research started coverage on Ovid Therapeutics in a research note on Thursday. They issued a "buy" rating and a $11.00 target price on the stock.December 19, 2023 | finance.yahoo.comS&W Seed Company Appoints Jeffrey Rona to Its Board of DirectorsDecember 1, 2023 | finance.yahoo.comOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide OVID Media Mentions By Week OVID Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼0.150.57▲Average Medical News Sentiment OVID News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼91▲OVID Articles Average Week Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATOS News GBIO News OMER News RENB News RIGL News GALT News MACK News TRVI News GTHX News LFCR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
